# Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI

> **NCT05594355** · PHASE4 · UNKNOWN · sponsor: **Fundació ACE Institut Català de Neurociències Aplicades** · enrollment: 100 (actual)

## Conditions studied

- Mild Cognitive Impairment (MCI)

## Interventions

- **DRUG:** TEBOFORTAN

## Key facts

- **NCT ID:** NCT05594355
- **Lead sponsor:** Fundació ACE Institut Català de Neurociències Aplicades
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-04-16
- **Primary completion:** 2023-12
- **Final completion:** 2023-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594355, "Effect of Treatment With EGb 761(r) on Blood Markers of Inflammation and Oxidative Stress in Patients With MCI". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05594355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*